Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
178.50
+1.50 (0.85%)
Jul 30 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 176.50 - 179.50
52 week 1.13 - 179.50
Open 178.50
Vol / Avg. 440,603.00/551,864.00
Mkt cap 722.10M*
P/E 218.22
Div/yield     -
EPS 0.01*
Shares 406.20M
Beta     -
Inst. own     -
*GBP
Jun 24, 2015
Vectura Group PLC at ROTH Healthcare Day - London
Jun 2, 2015
Vectura Group PLC at Jefferies Global Healthcare Conference
  

Key stats and ratios

Q1 (Mar '15) 2015
Net profit margin 21.24% 6.38%
Operating margin 0.26% -12.07%
EBITD margin - 26.03%
Return on average assets 5.61% 1.23%
Return on average equity 7.43% 1.65%
Employees 243 -
CDP Score - 74 C

Address

One Prospect West
CHIPPENHAM, SN14 6FH
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies. Its portfolio comprises partnered and licensed marketed products, as well as branded and generic investigational drugs. It has various products in the pipeline, which include VR588, VR942, VR475, VR465, VR096, VR647, VR179, VR736, VR876, NVA237, QVA149, VR315, VR506 and VR632. Its marketed products include Ultibro Breezhaler, Seebri Breezhaler, AirFluSal Forspiro, ADVATE and Adept. Its licensed products include Anoro Ellipta, Relvar Ellipta/Breo Ellipta and Incruse Ellipta. It also has a range of technology platforms, which include formulation technologies, such as PowderHale and ParticleMAX, and device technology, such as GyroHaler.

Officers and directors

Trevor Michael Phillips Ph.D. Chief Operating Officer, President - US Operations, Director
Age: 54
Andrew J. Oakley Group Chief Financial Officer, Executive Director, Company Secretary
Age: 53
Gerard Scheuch Chief Scientific Officer
Age: 58
Joanne Hombal Director of Human Resources
Age: 41
Roger Heerman Chief Commercial Officer
Age: 42
Karl D. Keegan Ph.D. Chief Corporate Development Officer
Age: 48
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 68
Per-Olof Andersson Non-Executive Director
Age: 62
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 60
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 62